HNRNPC revealed as key RNA regulator with broad diagnostic and therapeutic potential

In a wide-ranging review that could reshape how scientists approach the diagnosis and treatment of multiple diseases, researchers in China have compiled the most comprehensive picture yet of HNRNPC, a master RNA-binding protein whose influence stretches from the fundamental mechanics of RNA processing to the progression of cancer, neuropsychiatric disorders, infectious disease, and metabolic dysfunction. The work, published in Cancer Cell International, positions this once-underappreciated nuclear protein as a candidate linchpin for precision medicine across an astonishing range of pathological conditions.

HNRNPC, or heterogeneous nuclear ribonucleoprotein C, belongs to a large family of RNA-binding proteins that patrol the nucleus of every human cell. Its core job is deceptively simple: it grabs onto newly made RNA molecules and helps decide their fate. But as the review by Zezhao Ji, Yanbin Peng, Abduxukur Ablimit, Zhiwei Liang, and Lixin Wang makes clear, that simple-sounding task cascades into nearly every layer of gene regulation. Through its RNA recognition motifs—the protein domains that physically clasp onto RNA—HNRNPC influences how pre-messenger RNA transcripts are spliced into their mature forms, how stable those transcripts are once assembled, how efficiently they are translated into proteins, and how they interact with the sprawling world of non-coding RNAs that fine-tune cellular behavior.

Perhaps the most consequential of HNRNPC’s functions involves N6-methyladenosine, or m⁶A, the most abundant chemical tag on messenger RNA in mammalian cells. This epitranscriptomic mark, added and removed by dedicated enzyme systems, acts like a molecular zip code that tells reader proteins how to handle a given transcript. HNRNPC functions as one of those readers, and it does so in an unusual way. Rather than recognizing the m⁶A mark directly, it binds methylated RNA regions indirectly, because the methyl group causes local structural changes in the RNA that expose sites HNRNPC prefers to occupy. The consequence is dramatic: by latching onto these regions, HNRNPC can open up or obscure binding sites for other splicing regulators, effectively rewriting the splicing patterns of hundreds of genes at once. The review emphasizes that HNRNPC can also act entirely independently of m⁶A, giving the protein dual modes of action that complicate but also enrich its biological portfolio.

The downstream consequences of this dual-mode regulation are anything but academic. In tumor cells, HNRNPC behaves as a volume knob for oncogenic programs. The review documents how aberrant HNRNPC expression promotes epithelial-mesenchymal transition, the cellular shape-shifting process through which cancer cells gain the mobility needed to invade surrounding tissue and seed metastases. It also modulates programmed death-ligand 1, or PD-L1, the molecular shield that tumors raise against immune attack, thereby influencing how cancer patients respond to immunotherapy. Levels of HNRNPC additionally correlate with tumor mutational burden, an established predictor of immunotherapy outcomes, suggesting that this RNA-binding protein sits at a junction between RNA metabolism and the immune landscape of cancer. Depending on context and target genes, HNRNPC can act either as an oncogene pushing disease forward or as a protective factor restraining it—a duality the authors stress must be resolved before the protein can be safely exploited in the clinic.

That dual nature reflects a broader theme of the review: HNRNPC is not a simple on-off switch. The protein is subject to an array of post-translational modifications that alter its behavior, and it operates within multiprotein complexes where other heterogeneous nuclear ribonucleoproteins and splicing factors modulate its reach. It also intersects with processes such as alternative polyadenylation, which determines where the tail of a messenger RNA is trimmed and extended, affecting transcript stability and translation efficiency. Through its interactions with long non-coding RNAs, circular RNAs, and microRNAs, HNRNPC participates in competing endogenous RNA networks in which different RNA species sequester one another’s regulators, producing ripple effects throughout the cell’s regulatory circuitry.

What elevates the review from molecular biology into clinical territory is its synthesis of HNRNPC’s role in diseases far beyond cancer. In neuropsychiatric conditions, disrupted HNRNPC function has been linked to aberrant RNA processing in neurons, where precisely calibrated splicing is critical for synaptic function and neural development. In reproductive and metabolic diseases, altered expression of the protein appears to disturb gene programs governing hormone responsiveness and energy homeostasis. The review also details HNRNPC’s entanglement with infectious and inflammatory disease: the protein engages with hepatitis B virus and hantavirus during infection, and it influences inflammatory signaling pathways, including effects on tumor necrosis factor alpha induced protein 6, an effector molecule in inflammatory cascades. These connections suggest that a single RNA-binding protein helps mediate how human cells respond to pathogens and inflammatory stress, opening potential avenues for antiviral and anti-inflammatory intervention.

The translational implications are captured in three distinct roles the authors assign to HNRNPC. As a diagnostic biomarker, abnormal HNRNPC expression profiles in patient tissues or biofluids could help identify disease earlier or classify it more precisely than current methods allow. As a prognostic predictor, the protein’s expression levels correlate with disease progression and poor clinical outcomes across multiple cancer types, meaning a simple measurement could inform how aggressively a tumor is likely to behave and which patients need closer surveillance. As a therapeutic target, HNRNPC is now within reach of emerging drug modalities. Antisense oligonucleotides, short synthetic strands that bind RNA with programmable specificity, could be designed to disrupt the HNRNPC-dependent splicing events that drive disease. Because HNRNPC’s pathogenic effects often run through m⁶A-dependent mechanisms, the growing pharmacopoeia of methyltransferase and demethylase inhibitors offers another route to indirect modulation.

The timing of this synthesis is significant. Epitranscriptomics, the study of chemical modifications to RNA, has moved from a niche curiosity to one of the fastest-growing fields in molecular biology over the past decade. The discovery that m⁶A marks recruit reader proteins such as HNRNPC to reshape RNA processing won foundational recognition and has since spawned a global effort to map, perturb, and therapeutically exploit the RNA modification landscape. HNRNPC sits squarely at the center of that effort, not only as an m⁶A reader but as a demonstrated example of how a modification can exert biological effects indirectly, through structural changes in the RNA rather than direct recognition. Understanding such indirect mechanisms is essential for the rational design of drugs targeting the m⁶A system, because inhibiting the writer enzymes may produce effects that propagate through multiple distinct reader proteins with different, sometimes opposing, consequences.

The authors are candid about the unresolved questions that temper enthusiasm. Context dependency remains the field’s central puzzle: the same protein can be oncogenic in one tissue and protective in another, and the determinants of that switch are only partially mapped. The precise structural basis of HNRNPC’s indirect recognition of methylated RNA regions has been worked out in model systems but not fully characterized across the diversity of human transcripts. The interplay between HNRNPC’s post-translational modifications and its RNA-binding preferences is largely unexplored. And translating laboratory findings into clinical biomarkers will require standardized assays, large patient cohorts, and prospective validation—none of which yet exist at scale. The review frames these gaps not as setbacks but as a research roadmap, identifying where focused investment is most likely to yield diagnostic and therapeutic dividends.

Funded by the Shanghai Municipal Key Clinical Discipline of Traditional Chinese Medicine Interdisciplinary Innovation Oncology and Shanghai Tongji Hospital, the work reflects a growing recognition in oncology research that the post-transcriptional layer of gene regulation is fertile ground for clinical innovation. The authors, drawn from Tongji Hospital, Shanghai Pulmonary Hospital, and Xinjiang Medical University, span pathology, integrated medicine, and basic medical science—an interdisciplinary blend suited to a subject that refuses to stay within any single organ system or disease category. Corresponding author Lixin Wang and colleagues argue that as epitranscriptomics matures, HNRNPC is positioned to become a core molecular target for the precision diagnosis and treatment of multiple diseases, a claim the review supports with a systematic accounting of the protein’s expression profiles, pathogenic mechanisms, and clinical associations across organ systems. For clinicians and drug developers, the message is that the era of targeting RNA-binding proteins is arriving, and HNRNPC is among the most compelling candidates to lead it. For patients, it means that a protein once known only to RNA biologists may soon appear in diagnostic panels and clinical trials that translate RNA biology into measurable survival gains.